[
    [
        {
            "time": "2018-02-01",
            "original_text": "复星医药：第七届董事会第五十二次会议(临时会议)决议公告",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事会",
                    "决议公告"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：第七届董事会第五十二次会议(临时会议)决议公告",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "智通港股公告精选︱2月1日",
            "features": {
                "keywords": [
                    "智通港股",
                    "公告精选",
                    "2月1日"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "港股"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智通港股公告精选︱2月1日",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "港股复盘：短线忧虑情绪上升 恒指2月开门下跌",
            "features": {
                "keywords": [
                    "港股复盘",
                    "短线忧虑",
                    "恒指",
                    "2月开门下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "港股"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "港股复盘：短线忧虑情绪上升 恒指2月开门下跌",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "[强于大市评级]生物医药行业动态跟踪报告：第二十六批拟纳入优先审评程序重点品种分析",
            "features": {
                "keywords": [
                    "强于大市评级",
                    "生物医药",
                    "优先审评",
                    "重点品种分析"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[强于大市评级]生物医药行业动态跟踪报告：第二十六批拟纳入优先审评程序重点品种分析",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "复星医药3款创新药获批临床 利妥昔单抗注射液有望成为国内首个生物类似药",
            "features": {
                "keywords": [
                    "复星医药",
                    "创新药",
                    "利妥昔单抗",
                    "生物类似药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药3款创新药获批临床 利妥昔单抗注射液有望成为国内首个生物类似药",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "[强烈推荐评级]复星医药(600196)事项点评：CD20靶点利妥昔单抗类似药纳入优先审评 上市步伐加快",
            "features": {
                "keywords": [
                    "强烈推荐评级",
                    "复星医药",
                    "CD20靶点",
                    "利妥昔单抗",
                    "优先审评",
                    "上市步伐加快"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[强烈推荐评级]复星医药(600196)事项点评：CD20靶点利妥昔单抗类似药纳入优先审评 上市步伐加快",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "中泰证券2月重点推荐标的",
            "features": {
                "keywords": [
                    "中泰证券",
                    "2月重点推荐",
                    "标的"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "证券"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰证券2月重点推荐标的",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "[INCREASE评级] CHUANCAI RESEARCH 2018 STRATEGY REPORT：2018 CHINA EQUITY MARKET PHARMACEUTICAL OUTLOOK",
            "features": {
                "keywords": [
                    "INCREASE评级",
                    "CHUANCAI RESEARCH",
                    "2018策略报告",
                    "医药展望"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[INCREASE评级] CHUANCAI RESEARCH 2018 STRATEGY REPORT：2018 CHINA EQUITY MARKET PHARMACEUTICAL OUTLOOK",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-02-01",
            "original_text": "复星集团：全球布局投资保险科技",
            "features": {
                "keywords": [
                    "复星集团",
                    "全球布局",
                    "投资",
                    "保险科技"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "保险科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星集团：全球布局投资保险科技",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        }
    ]
]